Focal Segmental Glomerulosclerosis (FSGS) Active Not Recruiting Phase 2 Trials for Atrasentan (DB06199)

Also known as: Focal Glomerulosclerosis / Glomerulosclerosis, Focal / Focal Segmental Glomerulosclerosis / Glomerulosclerosis, Focal Segmental / APOL1-mediated focal segmental glomerulosclerosis / Focal & segmental glomerulosclerosis / Focal glomerular sclerosis (disorder) / Focal segmental glomerulosclerosis (disorder)

IndicationStatusPhase
DBCOND0038485 (Focal Segmental Glomerulosclerosis (FSGS))Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04573920Atrasentan in Patients With Proteinuric Glomerular DiseasesTreatment